Zobrazeno 1 - 10
of 405
pro vyhledávání: '"Ross A, Soo"'
Autor:
Chia-Chi Lin, Elena Garralda, Patrick Schöffski, David S. Hong, Lillian L. Siu, Miguel Martin, Michela Maur, Rina Hui, Ross A Soo, Joanne Chiu, Tian Zhang, Brigette Ma, Chrisann Kyi, Daniel SW Tan, Philippe A. Cassier, John Sarantopoulos, Andrew Weickhardt, Richard D. Carvajal, Jennifer Spratlin, Taito Esaki, Fréderic Rolland, Wallace Akerley, Barbara Deschler-Baier, Lawrence Rispoli, Tanay S. Samant, Niladri Roy Chowdhury, Daniel Gusenleitner, Eunice L. Kwak, Vasileios Askoxylakis, Filippo De Braud
Publikováno v:
OncoImmunology, Vol 13, Iss 1 (2024)
ABSTRACTIeramilimab, a humanized anti-LAG-3 monoclonal antibody, was well tolerated in combination with the anti-PD-1 antibody spartalizumab in a phase 1 study. This phase 2 study aimed to further investigate the efficacy and safety of combination tr
Externí odkaz:
https://doaj.org/article/fba32163599d40e7abcb0008f2589a1a
Autor:
Ross Andrew Soo, Mark Doherty, Arjun Sahgal, Ai Peng Tan, Mei Chin Lim, Benjamin J Solomon, Kristy P Robledo, Yu Yang Soon, Chee Khoon Lee, Mark B Pinkham, Fiona Hegi-Johnson, Shilo Lefresne, Cheryl Ho, Adrian G Sacher, Alan Nichol, Ambika Parmar, David B Shultz, Ivan WK Tham, Jeremy Tey, Cheng Nang Leong, Wee Yao Koh, Yiqing Huang, Yvonne Li En Ang, Jiali Low, Clement Yong
Publikováno v:
BMJ Open, Vol 14, Iss 7 (2024)
Background Patients with advanced non-small-cell lung cancer (NSCLC) with activating mutations in the epidermal growth factor receptor (EGFR) gene are a heterogeneous population who often develop brain metastases (BM). The optimal management of patie
Externí odkaz:
https://doaj.org/article/d2149842a0cd4925972e09dd5e72943d
Autor:
Robert John Walsh, Rebecca Ong, Seng Wee Cheo, Peter Q.J. Low, Aishwarya Jayagopal, Matilda Lee, Natalie Ngoi, Samuel G. Ow, Andrea L.A. Wong, Siew Eng Lim, Yi Wan Lim, Valerie Heong, Raghav Sundar, Ross A. Soo, Cheng Ean Chee, Wei Peng Yong, Boon Cher Goh, Soo Chin Lee, David S.P. Tan, Joline S.J. Lim
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionMolecular profiling of metastatic breast cancer (MBC) through the widespread use of next-generation sequencing (NGS) has highlighted actionable mutations and driven trials of targeted therapy matched to tumour molecular profiles, with imp
Externí odkaz:
https://doaj.org/article/98dbdbab3f7349b688320adc069900de
Autor:
Yiqing Huang, Joseph J. Zhao, Yu Yang Soon, Alvin Wong, Folefac Aminkeng, Yvonne Ang, Yugarajah Asokumaran, Jia Li Low, Matilda Lee, Joan R. E. Choo, Gloria Chan, Adrian Kee, Sen Hee Tay, Boon Cher Goh, Ross A. Soo
Publikováno v:
Thoracic Cancer, Vol 13, Iss 22, Pp 3152-3161 (2022)
Abstract Background Durvalumab consolidation is associated with improved survival following concurrent chemoradiotherapy (CCRT) in patients with stage III non‐small cell lung cancer (NSCLC). Given the heterogeneity of stage III NSCLC patients, in t
Externí odkaz:
https://doaj.org/article/0da2bd43b8074adf9c375ef4e5a845d3
Autor:
Qing Zhou, MD, PhD, Ross A. Soo, MBBS, PhD, Gee-Chen Chang, MD, PhD, Chao-Hua Chiu, MD, Hidetoshi Hayashi, MD, PhD, Sang-We Kim, MD, PhD, Shunsuke Teraoka, MD, Yasushi Goto, MD, PhD, Jianying Zhou, MD, Victor Ho-Fun Lee, MD, Dong-Wan Kim, MD, PhD, Baohui Han, MD, PhD, James Chung Man Ho, MD, FRCP, Chia-Chi Lin, MD, PhD, Shun Lu, MD, Anna Polli, BS, Anna Maria Calella, PhD, Jean-François Martini, PhD, Chew Hooi Wong, PhD, Tony Mok, MD, Hye Ryun Kim, MD, PhD, Yi-Long Wu, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 5, Pp 100499- (2023)
Introduction: Lorlatinib is a potent, third-generation inhibitor of ALK. In the planned interim analysis of the ongoing, phase 3, randomized, global CROWN trial (NCT03052608), lorlatinib resulted in significantly longer progression-free survival than
Externí odkaz:
https://doaj.org/article/c09913d79c7448e094d8c942679bfbff
Autor:
Kumar Prabhash, Daniel Shao Weng Tan, Ross A. Soo, Piyada Sitthideatphaiboon, Yuh Min Chen, Pei Jye Voon, Elisna Syahruddin, Sojung Chu, Reto Huggenberger, Byoung-Chul Cho
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionStage III non-small cell lung cancer (NSCLC) is a heterogeneous disease requiring multimodal treatment approaches. KINDLE-Asia, as part of a real world global study, evaluated treatment patterns and associated survival outcomes in stage I
Externí odkaz:
https://doaj.org/article/0ada5bcfe735499cba04ad948b7874ec
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Epidermal growth factor receptor ( EGFR ) mutation is one of the key oncogenic mutations in non-small-cell lung cancer with adenocarcinoma histology. Exon 19 deletions and exon 21 L858R substitutions account for 90%, while EGFR exon 20 insertions con
Externí odkaz:
https://doaj.org/article/9e34ee396c6c488485432f6b68bfa4a7
Autor:
Abdul Rahman Jazieh, Huseyin Cem Onal, Daniel Shao-Weng Tan, Ross A. Soo, Kumar Prabhash, Amit Kumar, Reto Huggenberger, Byoung Chul Cho
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Background: Tyrosine kinase inhibitors (TKIs) are the standard of care for resectable and metastatic non-small-cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) mutations (EGFRm). We describe the real-world practice of EGFRm
Externí odkaz:
https://doaj.org/article/346f0d01f55749cd9795ce7d7269daa2
Autor:
Yvonne L. E. Ang, Gwo Fuang Ho, Ross A. Soo, Raghav Sundar, Sing Huang Tan, Wei Peng Yong, Samuel G. W. Ow, Joline S. J. Lim, Wan Qin Chong, Phyu Pyar Soe, Bee Choo Tai, Lingzhi Wang, Boon Cher Goh, Soo-Chin Lee
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-10 (2020)
Abstract Background We previously reported that low-dose, short-course sunitinib prior to neoadjuvant doxorubicin-cyclophosphamide (AC) normalised tumour vasculature and improved perfusion, but resulted in neutropenia and delayed subsequent cycles in
Externí odkaz:
https://doaj.org/article/64ad21aacf0e4e9dbb97e7c6812136d7
Autor:
Tian Zhang, Filippo de Braud, Taito Esaki, Wallace Akerley, Chrisann Kyi, Richard D Carvajal, Daniel Gusenleitner, Patrick Schöffski, Miguel Martin, David S Hong, Amy Prawira, Jürgen Krauß, Nidhi Patel, Rina Hui, Andrew Weickhardt, Niladri Roy Chowdhury, Daniel S W Tan, María Ochoa-de-Olza, John Sarantopoulos, Ross A Soo, Michela Maur, Barbara Deschler-Baier, Allen Lau, Tanay S Samant, Tyler Longmire, Catherine A Sabatos-Peyton, Radha Ramesh, Tiancen Hu, Ana Carion, Padmaja Yerramilli-Rao, Vasileios Askoxylakis, Eunice L Kwak
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 2 (2022)
Background Lymphocyte-activation gene 3 (LAG-3) is an inhibitory immunoreceptor that negatively regulates T-cell activation. This paper presents preclinical characterization of the LAG-3 inhibitor, ieramilimab (LAG525), and phase I data for the treat
Externí odkaz:
https://doaj.org/article/c14ae2c468844f0d8af45992b1b6b8f2